Tumor-intrinsic subtypes of pancreatic cancer are characterized by distinct kinomes that shed light on subtype-specific vulnerabilities such as receptor tyrosine kinases, including EGFR, in basal-like tumors.

Attorneys general representing 22 states sued the Trump administration today over its decision to reduce NIH support for indirect research costs—maintenance, utilities, personnel, and the like—for grant recipients (Cancer Discov 2025 Feb 9 [Epub]). The lawsuit, which was filed in the U.S. District Court for the District of Massachusetts, states that the NIH’s “unlawful” action “will devastate critical public health research at universities and research institutions” and predicts that “cutting-edge work to cure and treat human disease will grind to a halt.” The attorneys general argue that the NIH decision violates the Administrative Procedure Act, which governs how federal agencies establish regulations, because the move is not only “arbitrary and capricious,” but it also violates congressional appropriations law, which prohibits NIH from changing indirect cost rates.

A bipartisan group of senators reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, which would expand Medicare coverage to include certain FDA-approved MCED tests, blood tests that simultaneously screen for biomarkers of multiple cancer types. Coverage will not begin until 2028, according to the bill, at which point individuals ages 68 and younger will be covered. Each subsequent year, coverage will increase by one year; in 2029, for example, individuals ages 69 and younger will be covered. The bill received overwhelming support at the committee level in the previous Congress but was not voted on before the current Congress took office.